Can Week 4 PASI Response Serve as an Early Predictor of Apremilast Efficacy in Psoriasis? A Single-Centre Preliminary Study
DOI:
https://doi.org/10.2340/actadv.v105.44624Keywords:
apremilast, psoriasis, treatment efficacy, PASI Response Rates, clinical decision-makingDownloads
References
Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and safety trial evaluating the effects of apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol 2015; 73: 37–49. DOI: https://doi.org/10.1016/j.jaad.2015.03.049
Keating GM. Apremilast: a review in psoriasis and psoriatic arthritis. Drugs 2017; 77: 459–472. DOI: https://doi.org/10.1007/s40265-017-0709-1
Kelly JB 3rd, Foley P, Strober BE. Current and future oral systemic therapies for psoriasis. Dermatol Clin 2015; 33: 91–109. DOI: https://doi.org/10.1016/j.det.2014.09.008
Nash P, Ohson K, Walsh J, Delev N, Nguyen D, Teng L, et al. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis 2018; 77: 690–698. DOI: https://doi.org/10.1136/annrheumdis-2017-211568
Strober B, Alikhan A, Lockshin B, Shi R, Cirulli J, Schafer P. Apremilast mechanism of efficacy in systemic-naive
patients with moderate plaque psoriasis: pharmacodynamic results from the UNVEIL study. J Dermatol Sci 2019; 96: 126–133. DOI: https://doi.org/10.1016/j.jdermsci.2019.09.003
Okubo Y, Takahashi H, Hino R, Endo K, Kikuchi S, Ozeki Y, et al. Efficacy and safety of apremilast in the treatment of patients with mild-to-moderate psoriasis in Japan: results from PROMINENT, a phase 3b, open-label, single-arm study. Dermatol Ther (Heidelb) 2022; 12: 1469–1480. DOI: https://doi.org/10.1007/s13555-022-00747-5
Nast A, Dilleen M, Liyanage W, Aikman L, Szczypa P, Dressler C. Time, Psoriasis Area and Severity Index and Dermatology Life Quality Index of patients with psoriasis who drop out of clinical trials on etanercept because of lack of efficacy: a pooled analysis from 10 clinical trials. Br J Dermatol 2018; 178: 400–405. DOI: https://doi.org/10.1111/bjd.15864
Additional Files
Published
How to Cite
License
Copyright (c) 2025 Seyma Nur Erol, Selda Pelin Kartal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
